Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Up 1.3% - Here's Why

Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) shares rose 1.3% during mid-day trading on Thursday . The company traded as high as $1.66 and last traded at $1.62. Approximately 1,119,544 shares were traded during mid-day trading, a decline of 50% from the average daily volume of 2,243,243 shares. The stock had previously closed at $1.60.

Wall Street Analyst Weigh In

TSHA has been the subject of a number of recent research reports. Canaccord Genuity Group raised their target price on Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a "buy" rating in a research note on Friday, November 15th. Chardan Capital reissued a "buy" rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Thursday, November 14th. JMP Securities reissued a "market outperform" rating and set a $5.00 price objective on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Needham & Company LLC reissued a "buy" rating and set a $6.00 price objective on shares of Taysha Gene Therapies in a research report on Monday, January 6th. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Taysha Gene Therapies has a consensus rating of "Buy" and an average target price of $6.63.

Taysha Gene Therapies Stock Up 0.6 %

The business has a fifty day moving average of $1.77 and a 200 day moving average of $2.01. The company has a market capitalization of $334.05 million, a PE ratio of 2.59 and a beta of 0.92. The company has a current ratio of 5.51, a quick ratio of 5.51 and a debt-to-equity ratio of 0.48.

Hedge Funds Weigh In On Taysha Gene Therapies

Several hedge funds and other institutional investors have recently made changes to their positions in TSHA. Ground Swell Capital LLC purchased a new position in shares of Taysha Gene Therapies in the 4th quarter valued at about $25,000. Creative Planning purchased a new position in shares of Taysha Gene Therapies in the 3rd quarter valued at about $28,000. Cibc World Markets Corp purchased a new position in shares of Taysha Gene Therapies in the 4th quarter valued at about $28,000. E Fund Management Co. Ltd. purchased a new position in shares of Taysha Gene Therapies in the 4th quarter valued at about $31,000. Finally, Hsbc Holdings PLC boosted its stake in shares of Taysha Gene Therapies by 65.6% in the 4th quarter. Hsbc Holdings PLC now owns 20,391 shares of the company's stock valued at $36,000 after buying an additional 8,076 shares during the period. Hedge funds and other institutional investors own 77.70% of the company's stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.